<DOC>
	<DOCNO>NCT02234362</DOCNO>
	<brief_summary>The broad goal study examine efficacy tolerability vortioxetine ( flexible dose ) treatment major depressive disorder ( MDD ) symptomatic woman around menopausal transition . We hypothesize eight-week treatment vortioxetine promote significant improvement depression symptom menopause-related physical symptom .</brief_summary>
	<brief_title>Vortioxetine Menopausal Depression</brief_title>
	<detailed_description>Twenty-five peri- postmenopausal woman enrol open-label study . This 8-week intervention use open-label vortioxetine flexible dose 5-20 mg , dependent participant response tolerability . In addition assessment depressive symptom , improvement menopause-related physical emotional symptom occur MDD , include vasomotor symptom , cognition , fatigue , anxiety , sleep complaint , quality life , also examine .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>1 . Women age 4062 year perimenopausal early postmenopausal ( within 5 year last menstrual period surgically postmenopausal ) , include : 1 . Perimenopausal woman experience change menstrual cycle frequency duration , and/or physical symptom indicative menopausal transition , determine clinician 2 . Women use Mirena Intrauterine Device ( IUD ) , Folliclestimulating hormone ( FSH ) level &gt; 20 milliInternational unit/ml ( mIU/mL ) 2 . Women meet Diagnostic Statistical Manual Mental Disorders IV ( DSMIV ) criteria major depression ( assessed Mini International Neuropsychiatric Interview M.I.N.I . ) 3 . MADRS score least 20 baseline visit 4 . Women significant menopauserelated physical symptom , indicate follow criterion : 1 . Greene Climacteric Scale total score &gt; 20 ; 2 . Greene Climacteric Scale subscore vasomotor symptom &gt; 3 ; 3 . 14 bothersome hot flash per week ( selfreported ) . 5 . Signed informed consent . 1 . Pregnancy ( determined urine pregnancy test ) , intend pregnancy , breast feeding . 2 . Women whose primary diagnosis Panic Disorder , Obsessive Compulsive Disorder ( OCD ) , Generalized Anxiety Disorder ( GAD ) , Seasonal Affective Disorder ( SAD ) , Axis I pathology active within 6 month prior screen visit ( except specific phobia ) . Anxiety disorder allowable secondary MDD primary diagnosis . 3 . History current mania/hypomania , psychosis , bipolar disorder 4 . Regular treatment Selective Serotonin Reuptake Inhibitor ( SSRI ) Selective Norepinephrine Reuptake Inhibitors ( SNRI ) within 2 month prior screen visit 5 . Serious suicidal ideation intent 6 . Women use psychoactive centrally act medication within 2 week prior study screen 7 . Women receive hormonal intervention within 1 month prior study entry 8 . Known hypersensitivity vortioxetine inactive ingredient 9 . Treatment monoamine oxidase inhibitor ( MAOI ) within 14 day randomization potential need use MAOI study within 21 day discontinuation study drug 10 . Treatment linezolid intravenous methylene blue 11 . Patients severe hepatic impairment 12 . Uncontrolled hypertension ( &gt; 160/90 mmHg ) 13 . Resting heart rate &gt; 110/minute 14 . Any current severe unstable medical illness 15 . Not use medically approve method birth control , sexually active 12 month since last menstrual period 16 . Drug alcohol abuse past 1 year 17 . Use disallow medication ( specify Excluded Concomitant Medication section ) 18 . Concurrent enrollment another clinical trial Excluded Concomitant Medications : Selective estrogenreceptor modulators ( SERMs ) Hormone replacement therapy Hormonal contraceptive , exclude Mirena IUD Natural menopause supplement Episodic sleep medication ( chronic , regular , stabledose benzodiazepine allow ) Antidepressants Phytoestrogens Soybased medication Steroids Anorectics , appetite depressant</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>